RecruitingPhase 2NCT07072195

A Study of AMC6156 in People With Sarcopenia

Studying Neuromuscular disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Animuscure Inc.
Intervention
AMC6156 0.1mg(drug)
Enrollment
80 target
Eligibility
65 years · All sexes
Timeline
20252026

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07072195 on ClinicalTrials.gov

Other trials for Neuromuscular disease

Additional recruiting or active studies for the same condition.

See all trials for Neuromuscular disease

← Back to all trials